| 1 |
中华医学会感染病学分会，中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志，2019，27(12)：938-961.
|
| 2 |
Sawinski D, Blumberg EA. Infection in renal transplant recipients[M]//Himmelfarb Jonathan, Ikizler T. Alp. Chronic kidney disease, dialysis, and transplantation (4 edition). Philadelphia: Elsevier, 2019.
|
| 3 |
Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation[J]. Nat Rev Nephrol, 2015, 11(3): 172-182.
|
| 4 |
Morales JM, Campistol JM. Transplantation in the patient with hepatitis C[J]. J Am Soc Nephrol, 2000, 11(7): 1343-1353.
|
| 5 |
Daloul R, Pesavento TE, Goldberg DS, et al. A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients[J]. Kidney Int, 2021, 100(6): 1190-1198.
|
| 6 |
Zhang J, Sun W, Lin J, et al. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China[J]. BMC Infect Dis, 2019, 19(1): 1-6.
|
| 7 |
Reddy YNV, Nunes D, Chitalia V, et al. Hepatitis C virus infection in kidney transplantation‐changing paradigms with novel agents[J]. Hemodial Int, 2018, 22(Suppl 1): S53-S60.
|
| 8 |
Lai TS, Lee MH, Yang HI, et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study[J]. Hepatology, 2017, 66(3): 784-793.
|
| 9 |
Park H, Adeyemi A, Henry L, et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection[J]. J Viral Hepat, 2015, 22(11): 897-905.
|
| 10 |
Somerville L, Doucette K. Hepatitis C: current controversies and future potential in solid organ transplantation[J]. Curr Infect Dis Rep, 2018, 20(7): 1-10.
|
| 11 |
Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies[J]. World J Gastroenterol, 2014, 20(24): 7544-7554.
|
| 12 |
Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney[J]. Nat Rev Nephrol, 2019, 15(2): 73-86.
|
| 13 |
Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States[J]. Am J Kidney Dis, 2019, 75(1 Suppl 1)：A6-A7.
|
| 14 |
Cohen-Bucay A, Gordon CE, Francis JM. Non-immunological complications following kidney transplantation[J]. F1000Res, 2019, 8：F1000 Faculty Rev-194.
|
| 15 |
Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis[J]. Lancet Glob Health, 2016, 4(9): e609-e616.
|
| 16 |
Nakano T, Ninomiya T, Sumiyoshi S, et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study[J]. Am J Kidney Dis, 2010, 55(1): 21-30.
|
| 17 |
Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation[J]. J Am Coll Cardiol, 2012, 60(5): 434-480.
|
| 18 |
European Renal Best Practice Transplantation Guideline Development Group. ERBP guideline on the management and evaluation of the kidney donor and recipient[J]. Nephrol Dial Transplant, 2013, 28 Suppl 2: ii1-71.
|
| 19 |
Ramphul R, Fernandez M, Firoozi S, et al. Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol[J]. BMC Nephrol, 2018, 19(1): 1-12.
|
| 20 |
Weiner DE, Park M, Tighiouart H, et al. Albuminuria and allograft failure, cardiovascular disease events, and all-cause death in stable kidney transplant recipients: a cohort analysis of the FAVORIT trial[J]. Am J Kidney Dis, 2019, 73(1): 51-61.
|
| 21 |
Li S, Wang J, Zhang B, et al. Diabetes mellitus and cause-specific mortality: a population-based study[J]. Diabetes Metab J, 2019, 43(3): 319-341.
|
| 22 |
Fabrizi F, Martin P, Dixit V, et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies[J]. Am J Transplant, 2005, 5(10): 2433-2440.
|
| 23 |
Santos AH Jr, Chen C, Casey MJ, et al. New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology？[J]. Nephrol Dial Transplant, 2018, 33(1): 177-184.
|
| 24 |
Jeon HJ, Bae HJ, Ham YR, et al. Outcomes of end-stage renal disease patients on the waiting list for deceased donor kidney transplantation: a single-center study[J]. Kidney Res Clin Pract, 2019, 38(1): 116-123.
|
| 25 |
Fabiani S, Fallahi P, Ferrari SM, et al. Hepatitis C virus infection and development of type 2 diabetes mellitus: systematic review and meta-analysis of the literature[J]. Rev Endocr Metab Disord, 2018, 19(4): 405-420.
|
| 26 |
Ponticelli C, Favi E, Ferraresso M. New-Onset diabetes after kidney transplantation[J]. Medicina (Kaunas), 2021, 57(3): 250.
|
| 27 |
Rodrigo E, de Cos MA, Fernández-Fresnedo G, et al. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus. Transplantation proceedings[J]. Transplant Proc, 2005, 37(9): 3819-3820.
|
| 28 |
Liang J, Lv C, Chen M, et al. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation[J]. J Diabetes, 2019, 11(5): 370-378.
|
| 29 |
Chiu KC, Lee NP, Cohan P, et al. Beta cell function declines with age in glucose tolerant Caucasians[J]. Clin Endocrinol (Oxf), 2000, 53(5): 569-575.
|
| 30 |
Ma Y, Yan WW. Chronic hepatitis C virus infection and post-liver transplantation diabetes mellitus[J]. World J Gastroenterol, 2005, 11(39): 6085-6089.
|
| 31 |
Lin MV, Sise ME, Pavlakis M, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection[J]. PLoS One, 2016, 11(7): e0158431.
|
| 32 |
Durand C, Brown D, Wesson R, et al. EXPANDER-1: exploring renal transplants using hepatitis-C infected donors for HCV-negative recipients[C]. Am J Transplant, 2017, 17: 207.
|
| 33 |
Goldberg DS, Abt PL, Reese PP; THINKER Trial Investigators. Transplanting HCV-infected kidneys into uninfected recipients[J]. N Engl J Med, 2017, 377(11): 1105.
|
| 34 |
Eisenberger U, Guberina H, Willuweit K, et al. Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients[J]. Transplantation, 2017, 101(5): 980-986.
|
| 35 |
Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvir‐based antiviral therapy to treat hepatitis C virus infection after kidney transplantation[J]. Am J Transplant, 2016, 16(5): 1474-1479.
|
| 36 |
Fabrizi F, Alonso C, Palazzo A, et al. 'Real-life’experience with direct-acting antiviral agents for HCV after kidney transplant[J]. Ann Hepatol, 2021, 25: 100337.
|
| 37 |
Devresse A, Delire B, Lazarus JV, et al. Eliminating hepatitis C virus from a prevalent kidney transplant recipient population: a single-center study in Belgium in the direct-acting antivirals era[J]. Transplant Proc, 2020, 52(3): 815-822.
|
| 38 |
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2)：461-511.
|
| 39 |
Dashti-Khavidaki S, Khalili H, Nasiri-Toosi M. Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors[J]. Expert Rev Clin Pharmacol, 2018, 11(5): 525-529.
|
| 40 |
Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection[J]. Hepatology, 2020, 71(2): 686-721.
|
| 41 |
De A, Roy A, Verma N, et al. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: a systematic review and meta-analysis[J]. Nephrology, 2022, 27(1): 82-89.
|
| 42 |
Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease[J]. J Am Soc Nephrol, 2016, 27(8): 2238-2246.
|
| 43 |
Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: advances, limitations and unchartered territories[J]. J Viral Hepat, 2017, 24(6): 442-453.
|
| 44 |
El Helou G, Jay C, Nunez M. Hepatitis C virus and kidney transplantation: recent trends and paradigm shifts[J]. Transplant Rev (Orlando), 2022, 36(1)：100677.
|
| 45 |
Czarnecka P, Czarnecka K, Tronina O, et al. Utilization of HCV viremic donors in kidney transplantation: a chance or a threat？[J]. Ren Fail, 2022, 44(1): 434-449.
|
| 46 |
Feng Z, Zhang J, Tan W, et al. Efficacy and safety of direct-acting antivirals in kidney transplantation from HCV-viremic donors to negative recipients: a meta-analysis[J]. Front Med (Lausanne), 2022, 9：802686.
|
| 47 |
Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial[J]. Ann Intern Med, 2018, 168(8): 533-540.
|
| 48 |
Chen R, Li D, Zhang M, et al. Sofosbuvir/Velpatasvir prophylaxis for 12 weeks in hepatitis C virus (HCV)-negative recipients receiving kidney transplantation from HCV-positive donors[J]. Ann Transplant, 2021, 26: e933313-1.
|
| 49 |
冯成，杨洪吉，侯一夫，等. 直接抗病毒药物在肾移植丙型肝炎病毒患者中的应用[J/CD]. 实用器官移植电子杂志，2020, 8(2): 96-100.
|
| 50 |
Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease[J]. Gastroenterology, 2016, 150(7): 1590-1598.
|
| 51 |
Kahn JA. The use of organs from hepatitis C virus-viremic donors into uninfected recipients[J]. Curr Opin Organ Transplant, 2020, 25(6): 620-625.
|
| 52 |
King KL, Husain SA, Mohan S. Trends in transplantation center use of kidneys from deceased donors with positive hepatitis C virus nucleic acid testing[J]. Am J Kidney Dis, 2020, 76(5): 743-746.
|
| 53 |
Wang JH, Gustafson SK, Skeans MA, et al. OPTN/SRTR 2018 Annual Data Report: Hepatitis C[J]. Am J Transplant, 2020, 20 Suppl s1: 542-568.
|
| 54 |
Coppola N, Minichini C, Starace M, et al. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals[J]. J Med Virol, 2016, 88(10): 1659-1671.
|
| 55 |
Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients[J]. Am J Kidney Dis, 1997, 29(4): 608-614.
|